The U.S. Centers for Medicare & Medicaid Services (CMS) announces that Medicaid and the Children’s Health Insurance Program (CHIP) will stop paying for several gender-affirming treatments for children. The change includes puberty blockers, cross-sex hormones, and surgeries that support gender transition.
According to the outlets, the CMS decision is part of a policy shift tied to the Trump administration. Both sources describe CMS as characterizing the treatments as “experimental” and stating that the move is intended to protect children from procedures that the agency does not plan to cover under Medicaid or CHIP. They also frame the announcement as ending federal funding responsibility for these services.
While both reports align on what CMS ends funding and the general rationale given by the administration, they differ in wording and emphasis. One outlet focuses on the Medicaid termination of “child sex-change procedures” and highlights the agency’s criticism of the treatments; the other emphasizes the taxpayer angle and the administration’s stated intent to shield children from “experimental” care.
